Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
2004 · British Journal of Cancer · 49 citations
https://doi.org/10.1038/sj.bjc.6601634
S
Sara Donati
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
72
Papers
1.1K
Citations
18
h-index
29
i10-index
Sara Donati is an academic researcher. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies. The author has an h-index of 18, co-authored 62 publications.
Papers by this author
worksEvaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer
2011 · Journal of Experimental & Clinical Cancer Research · 15 citations
https://doi.org/10.1186/1756-9966-30-38
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study
2005 · British Journal of Cancer · 14 citations
https://doi.org/10.1038/sj.bjc.6602723
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
2022 · npj Breast Cancer · 11 citations
https://doi.org/10.1038/s41523-022-00400-6
Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report
2009 · Cases Journal · 4 citations
https://doi.org/10.1186/1757-1626-2-9133
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial
2024 · European Journal of Cancer · 1 citations
https://doi.org/10.1016/j.ejca.2024.115108
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat